Industryweek 4920 Pfizer
Industryweek 4920 Pfizer
Industryweek 4920 Pfizer
Industryweek 4920 Pfizer
Industryweek 4920 Pfizer

Justice Department Fines Pfizer Unit Wyeth $490.9 Million for Illegal Drug Marketing

July 30, 2013
Wyeth was accused of training its Rapamune sales force in the United States to promote the use of the drug in non-renal organ transplants and encouraged them to offer financial incentives to target all types of transplant patients to boost sales.

WASHINGTON - Wyeth Pharmaceuticals has pleaded guilty to misbranding a drug that prevents the rejection of organ transplants and agreed to pay $490.9 million, the US Justice Department said Tuesday.

The $490.9 million will resolve Wyeth's criminal and civil liability stemming from the unlawful marketing of the prescription drug Rapamune for uses not approved as safe and effective by the U.S. Food and Drug Administration.

In 1999, Wyeth received approval from the FDA for Rapamune use in renal, or kidney, transplant patients. The immunosuppressive drug prevents the body's immune system from rejecting a transplanted organ.

Wyeth was accused of training its Rapamune sales force in the United States to promote the use of the drug in non-renal organ transplants and encouraged them to offer financial incentives to target all types of transplant patients to boost sales.

The FDA had not authorized the so-called "off-label" uses.

"This was a systemic, corporate effort to seek profit over safety. Companies that ignore compliance with FDA regulations will face criminal prosecution and stiff penalties," Sanford Coats, U.S. attorney for the Western District of Oklahoma, said in a statement.

Wyeth pleaded guilty to a criminal a misbranding violation and has agreed to pay a criminal fine and forfeiture totaling $233.5 million, the Justice Department said.

The company, under a plea agreement that has been accepted by the U.S. District Court in Oklahoma City, also has agreed to pay a criminal fine of $157.58 million and forfeit assets of $76 million.

The government alleged that Wyeth also violated the False Claims Act, from 1998 through 2009, by promoting Papamune for unapproved purposes that resulted in false claims to government health-care programs.

U.S. pharmaceutical giant Pfizer (IW 500/17), which acquired Wyeth in October 2009, highlighted the agreement was between Wyeth and the Department of Justice, all 50 states and the District of Columbia.

"Pfizer was not a subject or target of this matter, and cooperated fully with the government from the time it learned of this investigation in October 2009," the company said in an email to AFP.

Pfizer in December 2012 agreed to pay $55 million to settle U.S. government allegations that Wyeth promoted an acid-reflux drug, Protonix, for unapproved uses between February 2000 and June 2001.

Pfizer denied the allegations in that civil complaint.

Copyright Agence France-Presse, 2013

Popular Sponsored Recommendations

ESOP’s and Employee Ownership Culture

March 18, 2024
Unlock the power of ESOPs & employee ownership culture! Learn how to build a strong foundation for success & engagement in your business.

Redefining the Cost-Quality Equation with Holistic MES+QMS

March 28, 2022
Today’s manufacturers are under pressure to meet two often-opposing objectives: delight customers with high-quality products, and continually reduce operational costs while doing...

Smarter Savings for Manufacturers - Guide

Sept. 12, 2023
Enhance your service experiences and boost revenue while reducing costs. Learn how one platform can help your business be more agile and productive in today's market.

You Cannot Stay Competitive by Bolting New Technologies to a Legacy ERP

Oct. 20, 2023
Read this white paper to understand the benefits of shifting to a next-generation ERP system as part of a DOP.

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!